Assertio Therapeutics (ASRT) Misses Q3 EPS by 14c

Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.01, $0.14 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $35.63 million versus the consensus estimate of $49.92 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Morgan Stanley Resumes Victoria Secret (VSXY) at Overweight
• Intercontinental Exchange (ICE) PT Lowered to $208 at Raymond James, 'we view the risk/reward as attractive'